What Takeda's Failed TOMMORROW Trial Means For Early Alzheimer's Today
The TOMMORROW study was revolutionary for its time in testing Actos early, before symptoms are apparent; failure is disappointing but similar metabolic approaches might still play a role, says the Alzheimer's Association.
You may also be interested in...
Karuna Therapeutics’ top-line Phase II data for a combination of a centrally acting muscarinic agonist, xanomeline, and a peripherally acting muscarinic antagonist, trospium, were greeted with enthusiasm by investors and the Boston, MA-based biotech.
Emerging Company Profile: The start-up's Phase I and II studies look promising for stem cell therapy in treating aging frailty, a common condition that overlaps with Alzheimer's disease.
Drug firms exploring link between inflammation and central nervous system disorders are now sharing resources through public/private Biomarkers Consortium project.